Lung Cancer | Specialty

Dr. Morris on Lymphopenia as a Predictor of Survival in CRT-Treated NSCLC

September 30th 2015

John Morris, MD, professor of Medicine, co-director, Comprehensive Lung Cancer Center, associate director, UCCI Translational Research and Director, Experimental Therapeutics, University of Cincinnatti, discusses lymphopenia as a predictor of survival in chemoradiation-treated non–small cell lung cancer.

Longer Follow-up Confirms Nivolumab OS Benefit in Nonsquamous NSCLC

September 28th 2015

Treatment with nivolumab reduced the risk of death by 28% compared with docetaxel for patients with previously treated nonsquamous non–small cell lung cancer.

Novel Antibody-Drug Conjugate Shows Promise in SCLC

September 28th 2015

The antibody-drug conjugate rovalpituzumab tesirine demonstrated activity across a range of patients with relapsed and refractory small-cell lung cancer.

Two Pivotal Studies Show Efficacy of Atezolizumab in PD-L1-Positive NSCLC

September 27th 2015

Inhibition of PD-L1 with atezolizumab demonstrated significant clinical efficacy as monotherapy in patients with advanced non-small cell lung cancer.

Everolimus May Be New Standard of Care in Advanced Lung, GI NETs

September 26th 2015

Treatment with everolimus was associated with a 52% improvement in median progression-free survival compared with placebo in patients with advanced lung and gastrointestinal neuroendocrine tumors.

Dr. Daly on Clinical Trials With Radiation Therapy in Lung Cancer

September 24th 2015

Megan E. Daly, MD, assistant professor of radiation oncology, UC Davis Cancer Center, discusses upcoming clinical trials involving radiation therapy for the treatment of lung cancer.

2015 World Conference on Lung Cancer

September 18th 2015

Dr. Roth Compares Surgery With SBRT in Lung Cancer

September 18th 2015

Jack A. Roth, MD, professor, Department of Thoracic and Cardiovascular Surgery, chief, Section of Thoracic Molecular Oncology, Division of Surgery, University of Texas MD Anderson Cancer Center, compares surgery with stereotactic body radiation therapy (SBRT) in patients with early-stage lung cancer.

How EGFR and PD-1 Pathway Agents May Change Lung Cancer Care

September 17th 2015

As new targeted and immunologic agents are introduced for patients with lung cancer, clinicians have more factors to consider than ever before when developing treatment plans for their patients.

Three Priority Review Designations, Zarxio Now Available, Rolapitant Approved, and More

September 11th 2015

Osimertinib Produces High Response Rate in EGFR T790M-Mutant NSCLC

September 10th 2015

The third-generation TKI osimertinib (AZD9291) showed a 71% objective response rate in patients with EGFR T790M-mutant non–small cell lung cancer following resistance to frontline anti-EGFR therapy.

Deep Sequencing Reveals Possible Primary Resistance Mechanism in EGFR-Mutant NSCLC

September 9th 2015

Coexisting driver mutations in EGFR-mutant non–small cell lung cancer could potentially contribute to primary resistance to EGFR-targeted therapy.

Cetuximab Improves Survival in EGFR-Positive Squamous NSCLC

September 9th 2015

The addition of cetuximab (Erbitux) to chemotherapy reduced the risk of death by 44% for patients with advanced squamous non–small cell lung cancer whose tumors test positive for EGFR gene amplification.

Survival Not Improved by Adjuvant Bevacizumab in NSCLC

September 9th 2015

The addition of bevacizumab (Avastin) to adjuvant chemotherapy did not improve overall survival in patients with surgically resected early-stage non–small cell lung cancer.

FDA Grants Alectinib Priority Review in NSCLC

September 9th 2015

Alectinib received an FDA priority review designation for patients with ALK-positive, locally advanced or metastatic non–small cell lung cancer (NSCLC) who have progressed or are intolerant to crizotinib (Xalkori).

Survival Trends Higher With Necitumumab in EGFR FISH-Positive Squamous NSCLC

September 9th 2015

Survival for patients with metastatic squamous non–small cell lung cancer whose tumors were positive for EGFR copy number as determined by FISH analysis tended to be better when the EGFR antibody necitumumab was added to their conventional chemotherapy.

Potential Role Revealed for EGFR Inhibition Beyond Progression in NSCLC

September 9th 2015

Continued treatment with gefitinib beyond progression exhibited a trend toward better outcomes in patients with T790M-negative non­–small cell lung cancer.

Dr. Bauml on a New Platform to Enhance Lung Cancer Clinical Trial Enrollment

September 9th 2015

Joshua M. Bauml, MD, assistant professor, University of Pennsylvania, discusses a novel IT platform designed to enhance lung cancer clinical trial enrollment.

Dr. Pelosof on the Increasing Incidence of Never Smokers in NSCLC

September 9th 2015

Lorraine Pelosof, MD, PhD, from The University of Texas Southwestern Medical Center, discusses a study looking at the incidence of never smokers diagnosed with non-small cell lung cancer (NSCLC).

Dr. Jänne on Biomarker Results From a Study of AZD9291

September 9th 2015

Pasi A. Jänne, MD, PhD, director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, discusses biomarker results from the AURA study of AZD9291.